CDT Equity Spotlights Sarborg’s Quantum Computing Advances in Solid-Form Pharmaceutical Development

CDT Equity Inc. (Nasdaq: CDT) has drawn attention to a significant development by Sarborg Limited, which announced the expansion of its Signature Intelligence platform to include quantum-assisted coformer selection through its dedicated quantum computing division, SarborgQ. This advancement marks a strategic move to integrate emerging quantum technologies with proprietary data and artificial intelligence to accelerate pharmaceutical solid-form development.

Sarborg’s initiative combines a proprietary database of over 850 coformers with agentic AI architecture and quantum computing capabilities. This combination is designed to support coformer selection across Sarborg’s existing intellectual property portfolio and future client projects. The company is developing quantum-assisted tools aimed at speeding up solid-form development processes, improving decision-making accuracy, and identifying differentiated co-crystal, salt, and other solid-form opportunities.

Initially, Sarborg plans to deploy these quantum-assisted capabilities within its own IP portfolio. The objective is to generate new patentable assets and enhance existing products. Additionally, Sarborg intends to offer these advanced tools to external partners engaged in formulation development programs, thereby expanding its commercial reach.

CDT Equity regards this development as a key milestone in the evolution of Sarborg’s Signature Intelligence platform. The practical application of SarborgQ demonstrates how quantum computing and agentic reasoning can be harnessed to accelerate intellectual property generation and improve development efficiency. This approach is expected to broaden commercial opportunities for Sarborg, both internally and in collaborations with third parties.

Andrew Regan, Chief Executive Officer of CDT Equity, commented on the announcement: "We are pleased to see Sarborg continuing to execute against its strategic roadmap and further expand the practical applications of its Signature Intelligence platform. The application of SarborgQ to solid-form development demonstrates how Sarborg is seeking to leverage quantum computing to accelerate intellectual property generation and strengthen the commercial potential of its existing asset portfolio, whilst also creating opportunities to support third-party development programmes.”

Sarborg’s full announcement is accessible via its website and through CDT Equity’s disclosures, providing detailed insights into the expansion of its quantum-assisted coformer selection capabilities.

CDT Equity Inc., originally established as Conduit Pharmaceuticals, is a data-driven biopharmaceutical development company focused on advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company leverages artificial intelligence, solid-form chemistry, and asset repositioning to accelerate novel treatment development. CDT is committed to creating shareholder value through licensing, strategic mergers and acquisitions, and positioning itself as a platform for transformative innovation.

This press release contains forward-looking statements subject to risks and uncertainties, including regulatory approvals, market competition, and the ability to realize anticipated benefits from business combinations and technological advancements. CDT cautions readers not to place undue reliance on these statements, which speak only as of the date made and are not guarantees of future performance.